692 Shares in Insulet Corporation $PODD Acquired by Ellevest Inc.

Ellevest Inc. acquired a new stake in shares of Insulet Corporation (NASDAQ:PODD) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 692 shares of the medical instruments supplier’s stock, valued at approximately $217,000.

Other hedge funds also recently bought and sold shares of the company. Advisors Preferred LLC acquired a new position in shares of Insulet in the 2nd quarter valued at $847,000. State of Michigan Retirement System lifted its holdings in Insulet by 0.5% during the second quarter. State of Michigan Retirement System now owns 19,100 shares of the medical instruments supplier’s stock worth $6,001,000 after acquiring an additional 100 shares in the last quarter. iA Global Asset Management Inc. lifted its holdings in Insulet by 18.8% during the second quarter. iA Global Asset Management Inc. now owns 5,209 shares of the medical instruments supplier’s stock worth $1,637,000 after acquiring an additional 823 shares in the last quarter. Tredje AP fonden grew its stake in Insulet by 17.4% in the second quarter. Tredje AP fonden now owns 6,387 shares of the medical instruments supplier’s stock valued at $2,007,000 after acquiring an additional 945 shares during the period. Finally, Simon Quick Advisors LLC bought a new stake in shares of Insulet in the second quarter worth about $385,000.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on PODD shares. Wells Fargo & Company lifted their price objective on Insulet from $330.00 to $350.00 and gave the company an “overweight” rating in a report on Friday, August 8th. Canaccord Genuity Group lifted their price target on shares of Insulet from $353.00 to $399.00 and gave the company a “buy” rating in a research note on Monday, September 29th. Piper Sandler upped their price target on shares of Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Barclays increased their price objective on shares of Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Insulet in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $362.68.

Insulet Price Performance

NASDAQ PODD opened at $323.40 on Friday. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. Insulet Corporation has a 12-month low of $230.05 and a 12-month high of $353.50. The company has a market capitalization of $22.77 billion, a PE ratio of 98.30, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. The firm’s 50 day moving average is $325.46 and its 200-day moving average is $308.84.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. During the same quarter last year, the firm earned $1.08 earnings per share. The firm’s revenue for the quarter was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insider Activity

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.39% of the stock is owned by company insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.